Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 4, 2005, Pages 2179-2186

  Zhao, Jing ^a   Dahle, Danielle ^a   Zhou, Yunli ^a   Zhang, Xun ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; DEMETHYLATION; DNA FLANKING REGION; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENOME IMPRINTING; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOPHYSIS TUMOR; MEG3 GENE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR DIAGNOSIS;

AZACITIDINE; BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; EXONS; HUMANS; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; MUTATION; PITUITARY NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEINS;

EID: 17844397712     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1848     Document Type: Article

References (33)

1. Asa SL, Ezzat S 2002 The pathogenesis of pituitary tumors. Nat Rev Cancer 2:836-849
2. Korbonits M, Morris DG, Nanzer A, Kola B, Grossman AB 2004 Role of regulatory factors in pituitary tumor formation. Front Horm Res 32:63-95
3. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A 2003 A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88:5119-5126
4. lacZ, an insertional mutation on mouse Chromosome 12 with parental origin-dependent phenotype. Mamm Genome 7:20-24
5. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F 2000 Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells 5:211-220
6. Schuster-Gossler K, Bilinski P, Sado T, Ferguson-Smith A, Gossler A 1998 The mouse Glt2 gene is differentially expressed during embryonic development, encodes mutiple alternatively spliced transcripts, and may act as an RNA. Dev Dyn 212:214-228
7. Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, Martuza RL, von Deimling A, Gusella JF, Houseal TW 1997 Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 14:611-616
8. Mutirangura A, Pornthanakasem W, Sriuranpong V, Supiyaphun P, Voravud N 1998 Loss of heterozygosity on chromosome 14 in nasopharyngeal carcinoma. Int J Cancer 78:153-156
9. Bando T, Kato Y, Ihara Y, Yamagishi F, Tsukada K, Isobe M 1999 Loss of heterozygosity of 14q32 in colorectal carcinoma. Cancer Genet Cytogenet 111:161-165
10. Itoyama T, Chaganti RS, Yamada Y, Tsukasaki K, Atogami S, Nakamura H, Tomonaga M, Ohshima K, Kikuchi M, Sadamori N 2001 Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 97:3612-3620
11. Zhang X, Danila DC, Katai M, Swearingen B, Klibanski A 1999 Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas. J Clin Endocrinol Metab 84:4652-4655
12. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X 2003 DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 278:462-470
13. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A 1995 Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386-1392
14. Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A 1990 Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336-340
15. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S 1990 Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427-1433
16. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S 1999 Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13:156-166
17. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL 2002 Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109:69-78
18. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, Bell SM, Combaret V, Puisieux A, Mighell AJ, Robinson PA, Inglehearn CF, Isaacs JD, Markham AF 2003 Real-time PCR based on SYBR-Green 1 fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 3:18
19. Kolomietz E, Marrano P, Yee K Thai B, Braude I, Kolomietz A, Chun K, Minkin S, Kamel-Reid S, Minden M, Squire JA 2003 Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia 17:1313-1323
20. Aarskog NK, Vedeler CA 2000 Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107:494-498
21. Ruiz-Ponte C, Loidi L, Vega A, Carracedo A, Barros F 2000 Rapid real-time fluorescent PCR gene dosage test for the diagnosis of DNA duplications and deletions. Clin Chem 46:1574-1582
22. Harada K, Nishizaki T, Ozaki S, Kubota H, Harada K, Okamura T, Ito H, Sasaki K 1999 Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization. Cancer Genet Cytogenet 112:38-41
23. Daniely M, Aviram A, Adams EF, Buchfelder M, Barkai G, Fahlbusch R, Goldman B, Friedman E 1998 Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. J Clin Endocrinol Metab 83:1801-1805
24. Jones PA, Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
25. Wylie AA, Murphy SK, Orton TC, Jirtle RL 2000 Novel imprinted DLK1/ GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome Res 10:1711-1718
26. Murphy SK, Wylie AA, Coveler KJ, Cotter PD, Papenhausen PR, Sutton VR, Shaffer LG, Jirtle RL 2003 Epigenetic detection of human chromosome 14 uniparental disomy. Hum Mutat 22:92-97
27. Bolon I, Gouyer V, Devouassoux M, Vandenbunder B, Wernert N, Moro D, Brambilla C, Brambilla E 1995 Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 147:1298-1310
28. Della Fazia MA, Servillo G, Sassone-Corsi P 1997 Cyclic AMP signalling and cellular proliferation: regulation of CREB and CREM. FEBS Lett 410:22-24
29. Hilger-Eversheim K, Moser M, Schorle H, Buettner R 2000 Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 260:1-12
30. Kucharczak J, Simmons MJ, Fan Y, Gelinas C 2003 To be, or not to be: NF-κB is the answer: role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22:8961-8982
31. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE 2004 Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23:936-944
32. Farrell WE, Clayton RN 2003 Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10:323-330
33. Kalebic T 2003 Epigenetic changes: potential therapeutic targets. Ann NY Acad Sci 983:278-285